SCIB 1

Drug Profile

SCIB 1

Alternative Names: Cancer vaccine - Scancell; ImmunoBody melanoma vaccine - Scancell; Melanoma vaccine TRP2 gp100 - Scancell; SCIB-1

Latest Information Update: 01 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scancell
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes - Malignant melanoma

Highest Development Phases

  • Phase I/II Malignant melanoma

Most Recent Events

  • 18 Jul 2018 Scancell plans a phase II trial for Malignant melanoma (Combination therapy, Late stage disease) in USA in the first half of 2019
  • 01 Dec 2017 Phase-I/II development for Malignant melanoma (Late-stage disease) is ongoing in United Kingdom (IM) (Scancell website, December 2017)
  • 13 Sep 2017 Scancell announces intention to submit an IND application with the US FDA for Malignant melanoma in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top